Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROMAPAR (chlorpromazine hydrochloride) by Pfizer is clinical pharmacology the precise mechanism whereby the therapeutic effects of chlorpromazine hydrochloride are produced is not known. Approved for schizophrenia, severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), the short-term treatment of hyperactive children and 5 more indications. First approved in 1980.
Drug data last refreshed 21h ago
CLINICAL PHARMACOLOGY The precise mechanism whereby the therapeutic effects of chlorpromazine hydrochloride are produced is not known. The principal pharmacological actions are psychotropic. It also exerts sedative and antiemetic activity. Chlorpromazine hydrochloride has actions at all levels of…
Worked on PROMAPAR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo